Eli Lilly and Company (NYSE:LLY) Trading 2.1% Higher - Here's Why

Key Points

• Eli Lilly shares rose 2.1% to approximately $1,138.96, supported by strong demand for Mounjaro and Zepbound and continued optimism about the company’s obesity-drug opportunity.
• Recent earnings exceeded expectations, with EPS of $8.38 and revenue of $22.97 billion, up 47.7% year over year. Analysts maintain a “Moderate Buy” consensus and an average price target of $1,295.39, while Citigroup sees roughly 45% potential upside.
• Competition and insider selling remain risks: Novo Nordisk’s Wegovy pill may be gaining traction faster than Lilly’s Foundayo, while Lilly executives have sold shares and regulators are challenging unauthorized versions of an experimental weight-loss drug.

Eli Lilly and Company (NYSE:LLY - Get Free Report) shares shot up 2.1% on Monday . The company traded as high as $1,153.95 and last traded at $1,138.9570. 2,113,752 shares traded hands during mid-day trading, a decline of 30% from the average session volume of 3,040,423 shares. The stock had previously closed at $1,115.70.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Citigroup sees substantial upside. Citigroup initiated a Street-high price target implying approximately 45% potential upside, arguing that Lilly’s earnings momentum and obesity-drug opportunity remain underappreciated. Eli Lilly Stock Has 45% Upside, Says Citigroup
• Positive Sentiment: Mounjaro and Zepbound demand remains a key growth driver. Recent earnings exceeded expectations, supported by strong patient uptake and revenue growth of nearly 48% year over year. Analysts have responded by raising price targets, with the latest median target cited at $1,350.
• Positive Sentiment: Competitive pressure may be working in Lilly’s favor. Novo Nordisk’s rebranding highlights the intensifying obesity-drug battle, but coverage portrays Lilly as gaining share and pressuring its rival. Novo Rebrands to Take on Lilly
• Neutral Sentiment: Novartis’s pelacarsen setback has limited direct impact. The failure could alter parts of the broader pharmaceutical pipeline landscape, but analysts expect little immediate effect on Lilly’s core obesity and diabetes franchises. Novartis Drug Race Update
• Negative Sentiment: Competition and product execution remain concerns. Novo Nordisk’s Wegovy pill reportedly has gained traction faster than Lilly’s Foundayo, potentially challenging Lilly’s oral obesity-drug growth outlook. Novo Nordisk May Outpace Eli Lilly
• Negative Sentiment: Insider selling is a cautionary signal. Four Lilly executives sold shares during the past six months, with no reported insider purchases. Ohio regulators are also seeking to curb unauthorized versions of an experimental Lilly weight-loss drug, creating potential safety and reputational risks. Ohio Moves Against Unapproved Weight-Loss Drugs

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. BMO Capital Markets reissued an "outperform" rating on shares of Eli Lilly and Company in a research note on Wednesday, September 9th. Guggenheim upped their price objective on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a report on Monday, July 13th. Wells Fargo & Company increased their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Jefferies Financial Group raised their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a "buy" rating in a report on Tuesday, June 9th. Finally, HSBC upped their price target on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $1,295.39.

Eli Lilly and Company Stock Performance

The firm has a fifty day moving average of $1,183.67 and a 200-day moving average of $1,073.30. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $1.07 trillion, a price-to-earnings ratio of 38.22, a PEG ratio of 1.38 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.Eli Lilly and Company's revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 36.53 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 10th. Shareholders of record on Friday, August 14th were issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date was Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is 23.22%.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. Insiders own 0.14% of the company's stock.

Hedge Funds Weigh In On Eli Lilly and Company

Several hedge funds have recently bought and sold shares of LLY. California State Teachers Retirement System raised its stake in Eli Lilly and Company by 120,133.2% in the 2nd quarter. California State Teachers Retirement System now owns 1,460,379,190 shares of the company's stock valued at $1,751,622,612,000 after purchasing an additional 1,459,164,568 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares during the last quarter. Capital World Investors boosted its stake in shares of Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company's stock worth $16,154,619,000 after purchasing an additional 61,851 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Eli Lilly and Company during the second quarter worth about $13,522,666,000. Finally, Norges Bank purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $12,976,634,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company's products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.